Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Background and aims The centenary of Archives of Disease in Childhood ( ADC ) presents an opportunity to reflect on a century ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback